Modern Vaccines Adjuvants Formulation

18-20 May 2016, Eigtveds Pakhus, Copenhagen, Denmark

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Wednesday 18th May 2016

08.30
Arrival & Registration

09:30-09:45
Welcome to Copenhagen & Opening Remarks
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)

SESSION 1:
Opening Plenary Session

Session Moderator: Erik Lindblad (Brenntag Biosector, Denmark)

09:45-10:15
‘Formulation development of TLR7/8 Ligands: Applications in influenza, HIV and amebiasis’
Chris Fox (IDRI, Seattle, Washington, USA)

10:15-10:45
‘Mechanism of action of liposomal vaccine delivery systems’
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)

10:45-11:00
Wrap-up by Session Moderator

11:00-11:30
Coffee Break & Poster Set-up

SESSION 2:
VACCINES & ADJUVANTS PROPERTIES

Session Moderator: Dennis Christensen (SSI, Copenhagen, Denmark)

11:30-12:00
‘Pathogen camouflage: Implications for vaccine design’
Oreda Boussadia 2, Frances Terry 1, Leonard Moise 1,2, William Martin 1 and Anne S. De Groot 1,2 (1 University of Rhode Island, Providence, Rhode Island, USA: 2 EpiVax, USA)

12:00-12.30
‘Microcrystalline tyrosine as a tested and registered adjuvant for use in prophylactic vaccines’
Martin Bachmann (University of Zurich, Zurich, Switzerland)

12:30-12.45
Wrap-up by Session Moderator

12.45-14.00
Lunch Break & Posters

SESSION 3:
Vaccine Design

Session Moderator: Nicolas Collin (University of Lausanne, Lausanne, Switzerland)

14:00-14:30
‘Chemical modification of HIV-1 Env to induce neutralising antibodies’
Quentin Sattentau (University of Oxford, Oxford, UK)

14.30-15.00
‘Recombinant MERS S nanoparticles induce neutralizing antibody that inhibits MERS-CoV in vivo
David Flyer (Novavax Inc, Gaithersburg, Maryland, USA)

15:00-15:20
‘Construction of novel vaccine adjuvants using RNA nanotechnology’
Peixuan Guo (University of Kentucky, Lexington, Kentucky, USA)

15:20-15:40
‘Insights to the mechanism of action of the mucosal adjuvant Endocine’
Anna-Karin Maltais (Eurocine Vaccines AB, Solna, Sweden)

15:40-16:00
Tea Break & Posters

SESSION 3 (Continued):
Vaccine Design

Session Moderator: Quentin Sattentau (University of Oxford, Oxford, UK)

16:00-16:30
‘The adjuvant properties of the toll-like receptor 7/8 agonist 3M-052’
Mark Tomai (3M Company, St Paul, Minnesota, USA)

16.30-16.50
‘Novel liposomal formulation for in vivo expansion of CD8 T cells against whole protein antigens’
Jackson K. Eby, Adrienne V. Li, Yunwei Sun and Peter C. DeMuth (Vedantra Pharmaceuticals, Inc., Cambridge, Massachusetts, USA)

16:50-17:10
‘Bacterial superglue enables easy development of efficient virus-like particle based vaccines’
Susan Thrane, Christoph M. Janitzek, Mette Ø. Agerbæk, Sisse B. Ditlev, Mafalda Resende, Morten A. Nielsen, Thor G. Theander, Ali Salanti and Adam F. Sander (University of Copenhagen and Copenhagen University Hospital, Copenhagen, Denmark)

17:10-17:25
Wrap-up by Session Moderator

17:30-19:30
Copenhagen Canal Boat Trip & Reception
Sponsored by Brenntag Biosector

Brenntag

 

MVAF 2016 Delegates

Login details will be supplied after you have registered for the event.


MVAF 2016 Sponsors

  • Aldevron
  • NatureGeneTherapy.com
  • Vaxart
  • Inovio
  • Brenntag
  • EVI
  • Bioaster
  • Seppic
  • NanoTemper Technologies
  • IDRI
  • hVIVO
  • Mucosis
  • DNAvaccine.com
  • Sanofi Pasteur
  • CureVac
  • IntraVacc
  • Pfizer

MVAF 2016 Downloads

MVAF 2016 Leaflet

MVAF 2016 Mailing List

Name
E-mail Address
What is 3+2-1?